The bill amends Social Security Act §1945 to let states create State Plan Amendments (SPAs) that provide health home services focused primarily on individuals with sickle cell disease (SCD), effective January 1, 2026. States whose SPAs are approved must ensure enrolled SCD patients receive dental and vision services regardless of the State’s existing comparability rules or whether those services are available to other Medicaid beneficiaries.
States that adopt an SCD-focused health home must submit a report after the first eight fiscal quarters of operation covering quality, access, and total expenditures for enrolled individuals, using measures specified by CMS. The Centers for Medicare & Medicaid Services must publish best practices for designing these SPAs by June 30, 2026, and the bill defines who counts as an eligible individual with SCD and what qualifies as sickle cell disease.
At a Glance
What It Does
The bill authorizes CMS to approve State plan amendments to provide health home services targeted to Medicaid enrollees with sickle cell disease, requires provision of dental and vision services to those enrollees, and mandates state reporting on quality, access, and expenditures. It also directs CMS to publish best practices and to specify the measures states must use in reports.
Who It Affects
State Medicaid agencies and their contractors (including managed care organizations), hematologists and SCD specialty clinics, dental and vision providers who will treat newly covered SCD patients, and Medicaid enrollees who have sickle cell disease. CMS operations and compliance teams will also be responsible for approvals, measure-setting, and guidance.
Why It Matters
This creates a disease‑focused carve‑out in the §1945 health home framework and overrides typical comparability rules for dental and vision for the targeted population, which could change benefit design and spending patterns. It also forces states to collect outcome and cost data that could shape future federal and state SCD policy and payment models.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill plugs a gap in Medicaid’s health home statute by letting states create health home programs centered on sickle cell disease. Rather than requiring health homes to be defined only by multiple chronic conditions, the amendment allows a state to submit a State Plan Amendment explicitly designed to serve eligible individuals with SCD.
CMS retains authority to approve such SPAs and to set the terms for reporting and measurement.
A central operational change is the mandate that any state with an approved SCD-focused SPA must ensure enrolled individuals receive dental and vision services. That mandate applies even if the state does not offer dental or vision benefits broadly to other Medicaid populations or if usual comparability rules would otherwise limit benefits.
The bill therefore creates a narrow exception to traditional Medicaid comparability for a defined clinical population.The bill also imposes data and transparency obligations. After the first eight fiscal quarters a state’s SPA is in effect, the state must report to CMS on care quality (with emphasis on recovery-relevant outcomes), access to care, and total health care expenditures for enrolled SCD patients.
CMS is required to specify the measures states must use, and to publish best practices on the CMS website by June 30, 2026, drawing on clinical guidelines and stakeholder consultations. Finally, the statute defines who counts as an eligible individual with sickle cell disease—tying the condition to inherited biallelic sickle cell genotypes verified by newborn screening or genetic testing—clarifying that the entitlement targets disease rather than trait carriers.
The Five Things You Need to Know
The amendment takes effect January 1, 2026—states may begin submitting sickle cell disease-focused SPAs after that date.
A state with an approved SCD-focused SPA must provide dental and vision services to enrolled SCD patients regardless of the state’s comparability rules or whether those benefits are available to other Medicaid beneficiaries.
States must submit a report to CMS after the first eight fiscal quarters the SPA is in effect addressing quality (with recovery-focused outcomes), access, and total expenditures for enrolled individuals.
CMS must specify the performance and expenditure measures states use in their reports and publish best practices for SCD-focused health homes by June 30, 2026.
The bill defines an “eligible individual with sickle cell disease” as a Medicaid-eligible person with SCD confirmed by newborn screening or genetic test, excluding sickle cell trait without disease.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s name: the “Sickle Cell Disease Comprehensive Care Act.” This is formal but signals the statute’s focus on comprehensive outpatient care for a narrowly defined clinical group rather than a general Medicaid policy change.
Add SCD as an allowable focus for health homes
The bill inserts language into subsection (a) and (h)(5) of §1945 to make clear that, beginning January 1, 2026, health homes may be designed specifically for eligible individuals with sickle cell disease. Practically, that means states can pursue SPAs under the existing health home authority but target enrollment criteria, provider networks, and care coordination activities to SCD patients. Because the amendment is internal to §1945, it uses the existing health home financing and federal match framework rather than creating a new entitlement.
State Plan Amendment pathway and guaranteed dental/vision benefits
Subsection (c)(5)(A) authorizes CMS to approve SCD-focused SPAs. Subsection (c)(5)(B) then imposes a non‑negotiable requirement: states with an approved SPA must ensure dental and vision services for enrolled SCD individuals. Crucially, the statute states this obligation applies irrespective of existing comparability rules, meaning the benefit is carved out for this population even if the state lacks broad dental or vision coverage. Administratively, states will need to define covered dental and vision services, update provider enrollment and payment policies, and reflect these benefits in benefit packages and managed care contracts.
Data collection, CMS measure-setting, and definitional boundaries
The statute requires a report after eight fiscal quarters covering quality, access, and expenditures for the enrolled population, and directs CMS to specify the applicable measures. It also commands CMS to publish best practices by June 30, 2026, developed with specialty societies and patient advocates. The bill’s definition of SCD ties eligibility to inherited biallelic sickle cell genotypes identified via newborn screening or genetic tests, which clarifies that SCD (not trait status) is the population intended. These mechanics create explicit expectations for states on measurement, data collection, and stakeholder engagement—operational matters that CMS will need to operationalize through guidance.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid enrollees with sickle cell disease—gain access to coordinated outpatient health home services plus dental and vision care that many currently lack, which can reduce pain crises and downstream hospitalizations if implemented effectively.
- Sickle cell specialty clinics and hematologists—can receive structured referrals, coordinated care payments, and integration with dental/vision and primary care, improving longitudinal management and revenue stability for outpatient services.
- Dental and vision providers—could see a new, systematically referred patient cohort and clearer reimbursement pathways for services tied to SCD care coordination.
- Patient advocacy organizations and public health researchers—benefit from mandated reporting and CMS best practices, which produce data and consensus guidance that can be used for advocacy, quality improvement, and future policy design.
Who Bears the Cost
- State Medicaid programs—must add or expand dental/vision benefits for the targeted population, update SPAs, manage enrollment and provider networks, and absorb near-term administrative and service costs (even where federal matching applies).
- Managed care organizations and provider networks—will need to redesign care coordination workflows, comply with new reporting metrics, and potentially accept different provider payment arrangements for integrated SCD health homes.
- Centers for Medicare & Medicaid Services—faces workload to approve SPAs, specify measures, publish best practices, and provide technical assistance, which may require reallocation of agency resources.
- Taxpayers/federal and state budgets—could see higher near-term Medicaid spending for expanded outpatient and dental/vision services, even if longer-term savings materialize from reduced hospitalizations.
Key Issues
The Core Tension
The central dilemma is choosing between targeted, comprehensive benefits for a small, high‑need population and the fiscal and administrative costs of delivering those benefits under Medicaid. The bill advances clinical integration and fills known care gaps for SCD, but it forces states and CMS to absorb program complexity and short‑term spending increases to achieve potential long‑term health gains and cost offsets—a trade-off with no guaranteed balance.
The bill compresses several implementation decisions into a short statutory amendment and leaves important details to CMS guidance and state program design. Key unknowns include the exact scope of dental and vision coverage the statute requires—are routine exams and preventive services sufficient, or must states cover prosthetics, restorative dentistry, or specialty ophthalmologic care related to SCD complications?
States will have to interpret that text or await CMS rulemaking, with material budgetary implications.
Reporting and measure-setting are another fraught area. The statute mandates reports after eight fiscal quarters and directs CMS to specify measures, but it does not require risk adjustment, specify data sources, or address how small-state sample sizes will affect statistical validity.
States and providers could face substantial administrative burden to collect clinical outcome data and link it to expenditures, and inconsistent measure selection could undercut comparability across states. Finally, by defining SCD as a biallelic inherited condition confirmed by testing, the bill excludes trait carriers and other hemoglobinopathies, which simplifies eligibility but may leave some patients with clinically relevant complications outside the program’s scope.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.